Tempus AI announced a collaboration with Verastem Oncology to develop a companion diagnostic (CDx) test. This partnership follows Tempus's completion of confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which led to the U.S. Food and Drug Administration’s (FDA) accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
LGSOC is a rare and highly recurrent form of ovarian cancer that disproportionately affects younger women and has a poor response rate to chemotherapy. Tempus’s FDA-approved xT CDx assay is being leveraged as an investigational assay in Verastem’s global Phase 3 RAMP-301 clinical trial.
The investigational assay prospectively assesses KRAS status in patients with recurrent LGSOC to group them into KRAS-mutation or KRAS-wild type cohorts for study analysis. This collaboration is a critical step in bringing targeted therapies to patients with recurrent KRAS-mutant LGSOC and expands the application of Tempus's xT CDx assay.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.